Eli Lilly and Company and the US National Institute of Allergy and Infectious Diseases will study baricitinib, a Lilly rheumatoid arthritis drug, as a potential treatment for people with COVID-19 It’s thought that baricitinib’s anti-inflammatory effect could help reduce the cytokine storm that COVID-19 can trigger in patients Ruxolitinib, a cancer treatment from Novartis and Regeneron, is also being tested for its potential to dampen the cytokine storm
Lilly to test baricitinib against COVID-19